Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat

Contributed by: PR Newswire

Tags

GESYNTA-PHARMA

More Like This

/C O R R E C T I O N -- Gesynta Pharma/

Gynica announces First-in-Human Clinical Trial of Novel IntraVag© Treatment for Endometriosis

PR Newswire associated0

Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation

Gedeon Richter: Medical Treatment of Endometriosis with a progressive approach

Organon to Present New Research on Access and Value at ISPOR 2026

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Vertex Announces Key Advancements Across Kidney Portfolio

Figure 1: Mean NPRS Over Time in Phase 3 Study of Acute Pain Following Abdominoplasty (Graphic: Business Wire)

Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain